Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA

A number of common cancers associated with high mortality and cancers more likely to affect Black patients receive disproportionate funding for research and advocacy. (Journal of Clinical Oncology)

The FDA declined to approve zolbetuximab for locally advanced unresectable/metastatic HER2-negative, CLDN 18.2-positive gastric cancer because of issues with a third-party manufacturing facility, Astellas Pharma announced.

The Department of Justice announced that Moffit Cancer Center and Research Institute in Tampa, Florida, agreed to pay more than $19.5 million to resolve civil liability related to alleged submission of improper claims to Medicare and other government healthcare programs.

The U.S. Preventive Services Task Force announced a public comment period, ending January 31, for a draft research proposal involving medications to reduce breast cancer risk.

Why did almost a third of patients who had surgery for breast cancer — breast conserving or mastectomy — bypass the nearest surgical center? (Cancer)

Having established a role in acute lymphoblastic leukemia, B-cell malignancies, and myeloma, CAR T-cell therapy showed promise in an early study of T-cell malignancies. (Baylor College of Medicine, Blood)

A sex-specific panel of 10 proteins identified 18 different types of cancer representing all major organs, opening a new possibility for early cancer detection. (BMJ Oncology)

Analysis of cellular changes in triple-negative breast cancer identified three patient subgroups whose tumors responded to different combinations of radiation therapy and immunotherapy, a step toward precision therapy for the aggressive disease. (Cedars-Sinai, Cancer Cell)

All women younger than 65 with newly diagnosed breast cancer should have testing for germline BRCA1/2 mutations, according to a new guideline from the American Society of Clinical Oncology and the Society of Surgical Oncology.